Մեթիլֆենիդատ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Մեթիլֆենիդատ" in Armenian language version.

refsWebsite

Global rank Armenian rank

142nih.gov

4^th place

3^rd place

88doi.org

2^nd place

4^th place

33semanticscholar.org

11^th place

428^th place

21web.archive.org

1^st place

12archive.org

6^th place

4harvard.edu

18^th place

38^th place

3drugs.com

399^th place

102^nd place

2nhs.uk

1,989^th place

322^nd place

2upenn.edu

702^nd place

444^th place

2clincalc.com

3,912^th place

1,857^th place

2fda.gov

447^th place

244^th place

1books.google.com

3^rd place

17^th place

1pharmaceutical-journal.com

low place

4,126^th place

1drugbank.ca

4,294^th place

5,404^th place

1worldcat.org

5^th place

10^th place

1jfponline.com

low place

1psu.edu

207^th place

1,078^th place

1essentialmeds.org

low place

1jsonline.com

1,392^nd place

4,540^th place

1gale.com

1,435^th place

6,483^rd place

1novartis.com

low place

1inchem.org

4,334^th place

1,756^th place

1nationalarchives.gov.uk

744^th place

864^th place

1cjcp.ca

low place

1rxlist.com

7,927^th place

5,060^th place

1medicines.org.uk

3,823^rd place

1,279^th place

archive.org

Stahl SM (2013 թ․ ապրիլի 11). Stahl's Essential Psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press. ISBN 978-1107686465.
Neinstein L (2009). Handbook of Adolescent Health Care. Philadelphia, PA: Wolters Kluwer Health / Lippincott Williams & Wilkins. ISBN 978-0-7817-9020-8. OCLC 226304727.^:722
Vitiello B (October 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–989. doi:10.1542/peds.108.4.983. PMID 11581454. S2CID 33417584.
Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. CiteSeerX 10.1.1.507.874. doi:10.1542/peds.111.1.179. PMID 12509574. S2CID 29956425.
Leonard BE, McCartan D, White J, King DJ (April 2004). «Methylphenidate: A review of its neuropharmacological, neuropsychological, and adverse clinical effects». Human Psychopharmacology. 19 (3): 151–180. doi:10.1002/hup.579. PMID 15079851. S2CID 21173346.
Agay N, Yechiam E, Carmel Z, Levkovitz Y (July 2010). «Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults». Psychopharmacology. 210 (4): 511–519. doi:10.1007/s00213-010-1853-4. PMID 20424828. S2CID 17083986.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). «Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration». Pharmacotherapy. 26 (10): 1501–1510. doi:10.1592/phco.26.10.1501. PMC 1794223. PMID 16999660.
Poulton A (August 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. doi:10.1136/adc.2004.056952. PMC 1720538. PMID 16040876.
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, և այլք: (March 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics». Clinical Pharmacology and Therapeutics. 81 (3): 346–353. doi:10.1038/sj.clpt.6100082. PMC 3188424. PMID 17339864.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, և այլք: (September 2013). «Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies». The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, և այլք: (August 2008). «Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence». Drug and Alcohol Dependence. 96 (3): 222–232. doi:10.1016/j.drugalcdep.2008.03.010. PMC 3652530. PMID 18468815.

books.google.com

Preedy VR (2016). Neuropathology of Drug Addictions and Substance Misuse. Vol. 3: General processes and mechanisms, prescription medications, caffeine and areca, polydrug misuse, emerging addictions, and non-drug addictions. Academic Press. էջ 651. ISBN 9780128006771. Արխիվացված օրիգինալից 2021 թ․ օգոստոսի 29-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.

cjcp.ca

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE (2006). «A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder». The Canadian Journal of Clinical Pharmacology. 13 (1): e50–e62. PMID 16456216. Արխիվացված է օրիգինալից (PDF) 2011 թ․ դեկտեմբերի 15-ին.

clincalc.com

«The Top 300 of 2020». ClinCalc. Վերցված է 2022 թ․ հոկտեմբերի 7-ին.
«Methylphenidate - Drug Usage Statistics». ClinCalc. Վերցված է 2022 թ․ հոկտեմբերի 7-ին.

doi.org

Robison LS, Ananth M, Hadjiargyrou M, Komatsu DE, Thanos PK (May 2017). «Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats». Journal of Neural Transmission. 124 (5): 655–667. doi:10.1007/s00702-017-1680-4. PMC 5400672. PMID 28116523.
Spencer RC, Devilbiss DM, Berridge CW (June 2015). «The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex». Biological Psychiatry. 77 (11): 940–950. doi:10.1016/j.biopsych.2014.09.013. PMC 4377121. PMID 25499957.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2022 թ․ մայիսի 26-ին. Վերցված է 2022 թ․ հունիսի 12-ին.
Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P (2016). «From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate». Current Neuropharmacology. 14 (1): 17–27. doi:10.2174/1570159x13666150407225902. PMC 4787280. PMID 26813119.
Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP (January 2019). «Use of cognitive enhancers: methylphenidate and analogs». European Review for Medical and Pharmacological Sciences. 23 (1): 3–15. doi:10.26355/eurrev_201901_16741. PMID 30657540. S2CID 58643522.
Repantis D, Bovy L, Ohla K, Kühn S, Dresler M (February 2021). «Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine». Psychopharmacology. 238 (2): 441–451. doi:10.1007/s00213-020-05691-w. PMC 7826302. PMID 33201262.
Arnsten AF, Li BM (June 2005). «Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions». Biological Psychiatry. 57 (11): 1377–1384. doi:10.1016/j.biopsych.2004.08.019. PMID 15950011. S2CID 22992765.
Bagot KS, Kaminer Y (April 2014). «Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: A systematic review». Addiction. 109 (4): 547–557. doi:10.1111/add.12460. PMC 4471173. PMID 24749160.
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O (December 2010). «The history of attention deficit hyperactivity disorder». Attention Deficit and Hyperactivity Disorders. 2 (4): 241–255. doi:10.1007/s12402-010-0045-8. PMC 3000907. PMID 21258430.
«Narcotics monitoring board reports 66% increase in global consumption of methylphenidate». The Pharmaceutical Journal. Royal Pharmaceutical Society. 294 (7853). 2015 թ․ մարտի 4. doi:10.1211/PJ.2015.20068042. Արխիվացված օրիգինալից 2018 թ․ դեկտեմբերի 19-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.
Fone KC, Nutt DJ (February 2005). «Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder». Current Opinion in Pharmacology. 5 (1): 87–93. doi:10.1016/j.coph.2004.10.001. PMID 15661631.
Capp PK, Pearl PL, Conlon C (May 2005). «Methylphenidate HCl: therapy for attention deficit hyperactivity disorder». Expert Review of Neurotherapeutics. 5 (3): 325–331. doi:10.1586/14737175.5.3.325. PMID 15938665. S2CID 43406596.
Greenfield B, Hechman L (January 2005). «Treatment of attention deficit hyperactivity disorder in adults». Expert Review of Neurotherapeutics. 5 (1): 107–121. doi:10.1586/14737175.5.1.107. PMID 15853481. S2CID 38706248.
Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V (2021 թ․ հունիսի 2). «Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity». Neuropsychiatric Disease and Treatment. 13: 1741–1751. doi:10.2147/NDT.S130444. PMC 5505611. PMID 28740389.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, և այլք: (November 2011). «ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit / hyperactivity disorder in children and adolescents». Pediatrics. 128 (5): 1007–1022. doi:10.1542/peds.2011-2654. PMC 4500647. PMID 22003063.
Vitiello B (October 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–989. doi:10.1542/peds.108.4.983. PMID 11581454. S2CID 33417584.
Hermens DF, Rowe DL, Gordon E, Williams LM (May 2006). «Integrative neuroscience approach to predict ADHD stimulant response». Expert Review of Neurotherapeutics. 6 (5): 753–763. doi:10.1586/14737175.6.5.753. PMID 16734523. S2CID 15971025.
Gilmore A, Milne R (2001). «Methylphenidate in children with hyperactivity: review and cost-utility analysis». Pharmacoepidemiology and Drug Safety. 10 (2): 85–94. doi:10.1002/pds.564. PMID 11499858. S2CID 22871134.
Huang YS, Tsai MH (July 2011). «Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge». CNS Drugs. 25 (7): 539–554. doi:10.2165/11589380-000000000-00000. PMID 21699268. S2CID 3449435.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, և այլք: (February 2002). «Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults». Journal of the American Academy of Child and Adolescent Psychiatry. 41 (2 Suppl): 26S–49S. doi:10.1097/00004583-200202001-00003. PMID 11833633.
Faraone SV, Wilens TE (2007). «Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion». The Journal of Clinical Psychiatry. 68 (11): 15–22. doi:10.4088/jcp.1107e28. PMID 18307377.
Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. CiteSeerX 10.1.1.507.874. doi:10.1542/peds.111.1.179. PMID 12509574. S2CID 29956425.
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, և այլք: (November 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)». The Cochrane Database of Systematic Reviews. 2016 (11): CD009885. doi:10.1002/14651858.CD009885.pub2. PMC 8763351. PMID 26599576. «the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects»
Cândido RC, Menezes de Padua CA, Golder S, Junqueira DR (January 2021). «Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults». The Cochrane Database of Systematic Reviews. Wiley. 1 (1): CD013011. doi:10.1002/14651858.cd013011.pub2. PMC 8092481. PMID 33460048.
Abelman DD (October 2017). «Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review». Harm Reduction Journal. 14 (1): 68. doi:10.1186/s12954-017-0194-6. PMC 5639593. PMID 28985738.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Fry JM (February 1998). «Treatment modalities for narcolepsy». Neurology. 50 (2 Suppl 1): S43–S48. doi:10.1212/WNL.50.2_Suppl_1.S43. PMID 9484423. S2CID 36824088.
Mitler MM (December 1994). «Evaluation of treatment with stimulants in narcolepsy». Sleep. 17 (8 Suppl): S103–S106. doi:10.1093/sleep/17.suppl_8.S103. PMID 7701190.
Dell'Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC (December 2014). «Wake-promoting pharmacotherapy for psychiatric disorders». Current Psychiatry Reports. 16 (12): 524. doi:10.1007/s11920-014-0524-2. PMID 25312027. S2CID 26314915.
Leonard BE, McCartan D, White J, King DJ (April 2004). «Methylphenidate: A review of its neuropharmacological, neuropsychological, and adverse clinical effects». Human Psychopharmacology. 19 (3): 151–180. doi:10.1002/hup.579. PMID 15079851. S2CID 21173346.
Bahji A, Mesbah-Oskui L (September 2021). «Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis». Journal of Affective Disorders. 292: 416–423. doi:10.1016/j.jad.2021.05.119. PMID 34144366.
Rozans M, Dreisbach A, Lertora JJ, Kahn MJ (January 2002). «Palliative uses of methylphenidate in patients with cancer: a review». Journal of Clinical Oncology. 20 (1): 335–339. doi:10.1200/JCO.20.1.335. PMID 11773187.
Smith KR, Kahlon CH, Brown JN, Britt RB (September 2021). «Methylphenidate use in geriatric depression: A systematic review». International Journal of Geriatric Psychiatry. 36 (9): 1304–1312. doi:10.1002/gps.5536. PMID 33829530. S2CID 233184870.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL (May 2018). «Pharmacological interventions for apathy in Alzheimer's disease». The Cochrane Database of Systematic Reviews. 5 (6): CD012197. doi:10.1002/14651858.CD012197.pub2. PMC 6494556. PMID 29727467.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 19-ին. Վերցված է 2018 թ․ նոյեմբերի 14-ին.
Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). «Psychostimulants and cognition: a continuum of behavioral and cognitive activation». Pharmacological Reviews. 66 (1): 193–221. doi:10.1124/pr.112.007054. PMC 3880463. PMID 24344115.
Agay N, Yechiam E, Carmel Z, Levkovitz Y (July 2010). «Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults». Psychopharmacology. 210 (4): 511–519. doi:10.1007/s00213-010-1853-4. PMID 20424828. S2CID 17083986.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). «Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration». Pharmacotherapy. 26 (10): 1501–1510. doi:10.1592/phco.26.10.1501. PMC 1794223. PMID 16999660.
Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). «Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing». Sports Medicine. 43 (5): 301–311. doi:10.1007/s40279-013-0030-4. PMID 23456493. S2CID 30392999.
Ornoy A (February 2018). «Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation». Pharmaceutical Research. 35 (3): 46. doi:10.1007/s11095-017-2323-z. PMID 29411149. S2CID 3663423.
Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). «Development of a rational scale to assess the harm of drugs of potential misuse». Lancet. 369 (9566): 1047–1053. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (September 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». BMC Psychiatry. Springer Science and Business Media LLC. 13 (1): 237. doi:10.1186/1471-244x-13-237. PMC 3852277. PMID 24074240.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Rissardo JP, Caprara AL (2020). «Oromandibular dystonia secondary to methylphenidate: A case report and literature review». Int Arch Health Sci. 7: 108–111. doi:10.4103/iahs.iahs_71_19 (inactive 2022 թ․ դեկտեմբերի 31). Արխիվացված օրիգինալից 2021 թ․ նոյեմբերի 15-ին. Վերցված է 2021 թ․ նոյեմբերի 15-ին – via Gale Academic OneFile.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2022 (link) CS1 սպաս․ չպիտակված ազատ DOI (link)
Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ (June 2013). «Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study». European Neuropsychopharmacology. 23 (6): 542–554. doi:10.1016/j.euroneuro.2012.06.004. PMID 22809706. S2CID 23148548.
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261 (inactive 2024 թ․ հունվարի 31). PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2024 (link)
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, և այլք: (March 2013). «Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents». Journal of Child Psychology and Psychiatry, and Allied Disciplines. 54 (3): 227–246. doi:10.1111/jcpp.12036. PMID 23294014.
Poulton A (August 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. doi:10.1136/adc.2004.056952. PMC 1720538. PMID 16040876.
Hinshaw SP, Arnold LE (January 2015). «ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge». Wiley Interdisciplinary Reviews. Cognitive Science. 6 (1): 39–52. doi:10.1002/wcs.1324. PMC 4280855. PMID 25558298.
Findling RL, Dinh S (March 2014). «Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)». CNS Drugs. 28 (3): 217–228. doi:10.1007/s40263-014-0141-y. PMC 3933749. PMID 24532028.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). «Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature». Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261. PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
«FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 20. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, և այլք: (November 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. doi:10.1056/NEJMoa1110212. PMC 4943074. PMID 22043968.
«FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 15. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, և այլք: (December 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. doi:10.1001/jama.2011.1830. PMC 3350308. PMID 22161946.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews. 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews (Systematic Review). 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Spiller HA, Hays HL, Aleguas A (July 2013). «Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management». CNS Drugs. 27 (7): 531–543. doi:10.1007/s40263-013-0084-8. PMID 23757186. S2CID 40931380.
Bruggisser M, Bodmer M, Liechti ME (2011). «Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets». Swiss Medical Weekly. 141: w13267. doi:10.4414/smw.2011.13267. PMID 21984207.
Nestler EJ, Barrot M, Self DW (September 2001). «DeltaFosB: A sustained molecular switch for addiction». Proceedings of the National Academy of Sciences of the United States of America. 98 (20): 11042–11046. Bibcode:2001PNAS...9811042N. doi:10.1073/pnas.191352698. PMC 58680. PMID 11572966.
Nestler EJ (December 2012). «Transcriptional mechanisms of drug addiction». Clinical Psychopharmacology and Neuroscience. 10 (3): 136–143. doi:10.9758/cpn.2012.10.3.136. PMC 3569166. PMID 23430970.
Morton WA, Stockton GG (October 2000). «Methylphenidate Abuse and Psychiatric Side Effects». Primary Care Companion to the Journal of Clinical Psychiatry. 2 (5): 159–164. doi:10.4088/PCC.v02n0502. PMC 181133. PMID 15014637.
Steiner H, van Waes V (January 2013). «Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants». Progress in Neurobiology. 100: 60–80. doi:10.1016/j.pneurobio.2012.10.001. PMC 3525776. PMID 23085425.
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (June 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. doi:10.1093/sleep/28.6.667. PMID 16477952.
Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). «Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens». Proceedings of the National Academy of Sciences of the United States of America. 106 (8): 2915–2920. Bibcode:2009PNAS..106.2915K. doi:10.1073/pnas.0813179106. PMC 2650365. PMID 19202072.
Nestler EJ (December 2013). «Cellular basis of memory for addiction». Dialogues in Clinical Neuroscience. 15 (4): 431–443. doi:10.31887/DCNS.2013.15.4/enestler. PMC 3898681. PMID 24459410.
Ruffle JK (November 2014). «Molecular neurobiology of addiction: what's all the (Δ)FosB about?». The American Journal of Drug and Alcohol Abuse. 40 (6): 428–437. doi:10.3109/00952990.2014.933840. PMID 25083822. S2CID 19157711.
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (April 2008). «Serotonin syndrome induced by augmentation of SSRI with methylphenidate». Psychiatry and Clinical Neurosciences. 62 (2): 246. doi:10.1111/j.1440-1819.2008.01767.x. PMID 18412855. S2CID 5659107.
Türkoğlu S (2015). «Serotonin syndrome with sertraline and methylphenidate in an adolescent». Clinical Neuropharmacology. 38 (2): 65–66. doi:10.1097/WNF.0000000000000075. PMID 25768857. S2CID 38523209.
Park YM, Jung YK (May 2010). «Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (4): 719–720. doi:10.1016/j.pnpbp.2010.03.016. PMID 20298736. S2CID 31984813.
Patrick KS, González MA, Straughn AB, Markowitz JS (January 2005). «New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder». Expert Opinion on Drug Delivery. 2 (1): 121–143. doi:10.1517/17425247.2.1.121. PMID 16296740. S2CID 25026467.
Markowitz JS, Logan BK, Diamond F, Patrick KS (August 1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–366. doi:10.1097/00004714-199908000-00013. PMID 10440465.
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, և այլք: (March 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics». Clinical Pharmacology and Therapeutics. 81 (3): 346–353. doi:10.1038/sj.clpt.6100082. PMC 3188424. PMID 17339864.
Roberts SM, DeMott RP, James RC (1997). «Adrenergic modulation of hepatotoxicity». Drug Metabolism Reviews. 29 (1–2): 329–353. doi:10.3109/03602539709037587. PMID 9187524.
Markowitz JS, Patrick KS (June 2008). «Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter?». Journal of Clinical Psychopharmacology. 28 (3 Suppl 2): S54–S61. doi:10.1097/JCP.0b013e3181733560. PMID 18480678.
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (February 2007). «Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity». Behavioural Pharmacology. 18 (1): 39–51. doi:10.1097/fbp.0b013e3280143226. PMID 17218796. S2CID 20232871.
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (December 2006). «A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study». Journal of Child and Adolescent Psychopharmacology. 16 (6): 687–698. doi:10.1089/cap.2006.16.687. PMID 17201613. S2CID 22895177.
Heal DJ, Pierce DM (2006). «Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system». CNS Drugs. 20 (9): 713–738. doi:10.2165/00023210-200620090-00002. PMID 16953648. S2CID 39535277.
Iversen L (January 2006). «Neurotransmitter transporters and their impact on the development of psychopharmacology». British Journal of Pharmacology. 147 (Suppl 1): S82–S88. doi:10.1038/sj.bjp.0706428. PMC 1760736. PMID 16402124.
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002 թ․ հունվարի 1). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. doi:10.1177/070674370200601s05. PMID 12685517. S2CID 9132302.
Hodgkins P, Shaw M, Coghill D, Hechtman L (September 2012). «Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options». European Child & Adolescent Psychiatry. 21 (9): 477–492. doi:10.1007/s00787-012-0286-5. PMC 3432777. PMID 22763750.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, և այլք: (September 2013). «Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies». The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Frodl T, Skokauskas N (February 2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J (September 1996). «Relationship between psychostimulant-induced "high" and dopamine transporter occupancy». Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10388–10392. Bibcode:1996PNAS...9310388V. doi:10.1073/pnas.93.19.10388. PMC 38394. PMID 8816810.
Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, և այլք: (August 2008). «Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence». Drug and Alcohol Dependence. 96 (3): 222–232. doi:10.1016/j.drugalcdep.2008.03.010. PMC 3652530. PMID 18468815.
Heal DJ, Gosden J, Smith SL (December 2014). «Dopamine reuptake transporter (DAT) "inverse agonism" – a novel hypothesis to explain the enigmatic pharmacology of cocaine». Neuropharmacology. 87: 19–40. doi:10.1016/j.neuropharm.2014.06.012. PMID 24953830. S2CID 4660652.
Viggiano D, Vallone D, Sadile A (2004). «Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling». Neural Plasticity. 11 (1–2): 97–114. doi:10.1155/NP.2004.97. PMC 2565441. PMID 15303308.
Miller GM (January 2011). «The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity». Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
Eiden LE, Weihe E (January 2011). «VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse». Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.
Sulzer D, Cragg SJ, Rice ME (August 2016). «Striatal dopamine neurotransmission: regulation of release and uptake». Basal Ganglia. 6 (3): 123–148. doi:10.1016/j.baga.2016.02.001. PMC 4850498. PMID 27141430.
Volz TJ (December 2008). «Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate». Current Neuropharmacology. 6 (4): 379–385. doi:10.2174/157015908787386041. PMC 2701286. PMID 19587858.

drugbank.ca

«Methylphenidate». DrugBank. Արխիվացված է օրիգինալից 2019 թ․ հունվարի 31-ին. Վերցված է 2019 թ․ հունվարի 30-ին.

drugs.com

«Methylphenidate Hydrochloride Monograph for Professionals». Drugs.com. AHFS. Արխիվացված օրիգինալից 2018 թ․ դեկտեմբերի 19-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.
«Methylphenidate: Use During Pregnancy and Breastfeeding». Drugs.com. Արխիվացված է օրիգինալից 2018 թ․ հունվարի 2-ին.
«Concerta». Drugs.com. 2018 թ․ հոկտեմբերի 1. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 29-ին. Վերցված է 2019 թ․ մարտի 11-ին.

essentialmeds.org

list.essentialmeds.org

«eEML - Electronic Essential Medicines List». list.essentialmeds.org. Արխիվացված օրիգինալից 2020 թ․ մարտի 26-ին. Վերցված է 2020 թ․ մարտի 26-ին.

fda.gov

«Methylphenidate ADHD medications: Drug safety communication – risk of long-lasting erections». U.S. Food and Drug Administration (FDA). 2013 թ․ դեկտեմբերի 17. Արխիվացված է օրիգինալից 2013 թ․ դեկտեմբերի 17-ին. Վերցված է 2013 թ․ դեկտեմբերի 17-ին.
«FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 20. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, և այլք: (November 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. doi:10.1056/NEJMoa1110212. PMC 4943074. PMID 22043968.
«FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 15. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, և այլք: (December 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. doi:10.1001/jama.2011.1830. PMC 3350308. PMID 22161946.

gale.com

go.gale.com

Rissardo JP, Caprara AL (2020). «Oromandibular dystonia secondary to methylphenidate: A case report and literature review». Int Arch Health Sci. 7: 108–111. doi:10.4103/iahs.iahs_71_19 (inactive 2022 թ․ դեկտեմբերի 31). Արխիվացված օրիգինալից 2021 թ․ նոյեմբերի 15-ին. Վերցված է 2021 թ․ նոյեմբերի 15-ին – via Gale Academic OneFile.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2022 (link) CS1 սպաս․ չպիտակված ազատ DOI (link)

harvard.edu

ui.adsabs.harvard.edu

Nestler EJ, Barrot M, Self DW (September 2001). «DeltaFosB: A sustained molecular switch for addiction». Proceedings of the National Academy of Sciences of the United States of America. 98 (20): 11042–11046. Bibcode:2001PNAS...9811042N. doi:10.1073/pnas.191352698. PMC 58680. PMID 11572966.
Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). «Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens». Proceedings of the National Academy of Sciences of the United States of America. 106 (8): 2915–2920. Bibcode:2009PNAS..106.2915K. doi:10.1073/pnas.0813179106. PMC 2650365. PMID 19202072.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J (September 1996). «Relationship between psychostimulant-induced "high" and dopamine transporter occupancy». Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10388–10392. Bibcode:1996PNAS...9310388V. doi:10.1073/pnas.93.19.10388. PMC 38394. PMID 8816810.
Eiden LE, Weihe E (January 2011). «VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse». Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.

inchem.org

Heedes G, Ailakis J. «Methylphenidate hydrochloride (PIM 344)». INCHEM. International Programme on Chemical Safety. Արխիվացված օրիգինալից 2015 թ․ հունիսի 23-ին. Վերցված է 2015 թ․ հունիսի 23-ին.

jfponline.com

Mott TF, Leach L, Johnson L (August 2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–661. PMID 15298843. Արխիվացված է օրիգինալից 2011 թ․ հուլիսի 13-ին. Վերցված է 2009 թ․ ապրիլի 30-ին.

jsonline.com

Twohey M (2006 թ․ մարտի 26). «Pills become an addictive study aid». JS Online. Արխիվացված է օրիգինալից 2007 թ․ օգոստոսի 15-ին. Վերցված է 2007 թ․ դեկտեմբերի 2-ին.

medicines.org.uk

«Concerta XL 18 mg – 54 mg prolonged release tablets». eMC. Արխիվացված է օրիգինալից 2017 թ․ հոկտեմբերի 17-ին.

nationalarchives.gov.uk

webarchive.nationalarchives.gov.uk

Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE (2006). «A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder». The Canadian Journal of Clinical Pharmacology. 13 (1): e50–e62. PMID 16456216. Արխիվացված է օրիգինալից (PDF) 2011 թ․ դեկտեմբերի 15-ին.

nhs.uk

«Treatment». nhs.uk. Attention deficit hyperactivity disorder (ADHD) (անգլերեն). 2018 թ․ հունիսի 1. Վերցված է 2022 թ․ հոկտեմբերի 24-ին.
«Attention deficit hyperactivity disorder (ADHD): Treatment». National Health Service (NHS). 2021 թ․ դեկտեմբերի 24. Վերցված է 2022 թ․ հոկտեմբերի 18-ին.{{cite web}}: CS1 սպաս․ url-status (link)

nih.gov

pubmed.ncbi.nlm.nih.gov

Robison LS, Ananth M, Hadjiargyrou M, Komatsu DE, Thanos PK (May 2017). «Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats». Journal of Neural Transmission. 124 (5): 655–667. doi:10.1007/s00702-017-1680-4. PMC 5400672. PMID 28116523.
Spencer RC, Devilbiss DM, Berridge CW (June 2015). «The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex». Biological Psychiatry. 77 (11): 940–950. doi:10.1016/j.biopsych.2014.09.013. PMC 4377121. PMID 25499957.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2022 թ․ մայիսի 26-ին. Վերցված է 2022 թ․ հունիսի 12-ին.
Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P (2016). «From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate». Current Neuropharmacology. 14 (1): 17–27. doi:10.2174/1570159x13666150407225902. PMC 4787280. PMID 26813119.
Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP (January 2019). «Use of cognitive enhancers: methylphenidate and analogs». European Review for Medical and Pharmacological Sciences. 23 (1): 3–15. doi:10.26355/eurrev_201901_16741. PMID 30657540. S2CID 58643522.
Repantis D, Bovy L, Ohla K, Kühn S, Dresler M (February 2021). «Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine». Psychopharmacology. 238 (2): 441–451. doi:10.1007/s00213-020-05691-w. PMC 7826302. PMID 33201262.
Montgomery KA (June 2008). «Sexual desire disorders». Psychiatry. 5 (6): 50–55. PMC 2695750. PMID 19727285.
Arnsten AF, Li BM (June 2005). «Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions». Biological Psychiatry. 57 (11): 1377–1384. doi:10.1016/j.biopsych.2004.08.019. PMID 15950011. S2CID 22992765.
Bagot KS, Kaminer Y (April 2014). «Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: A systematic review». Addiction. 109 (4): 547–557. doi:10.1111/add.12460. PMC 4471173. PMID 24749160.
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O (December 2010). «The history of attention deficit hyperactivity disorder». Attention Deficit and Hyperactivity Disorders. 2 (4): 241–255. doi:10.1007/s12402-010-0045-8. PMC 3000907. PMID 21258430.
Fone KC, Nutt DJ (February 2005). «Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder». Current Opinion in Pharmacology. 5 (1): 87–93. doi:10.1016/j.coph.2004.10.001. PMID 15661631.
Capp PK, Pearl PL, Conlon C (May 2005). «Methylphenidate HCl: therapy for attention deficit hyperactivity disorder». Expert Review of Neurotherapeutics. 5 (3): 325–331. doi:10.1586/14737175.5.3.325. PMID 15938665. S2CID 43406596.
Greenfield B, Hechman L (January 2005). «Treatment of attention deficit hyperactivity disorder in adults». Expert Review of Neurotherapeutics. 5 (1): 107–121. doi:10.1586/14737175.5.1.107. PMID 15853481. S2CID 38706248.
Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V (2021 թ․ հունիսի 2). «Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity». Neuropsychiatric Disease and Treatment. 13: 1741–1751. doi:10.2147/NDT.S130444. PMC 5505611. PMID 28740389.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, և այլք: (November 2011). «ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit / hyperactivity disorder in children and adolescents». Pediatrics. 128 (5): 1007–1022. doi:10.1542/peds.2011-2654. PMC 4500647. PMID 22003063.
Vitiello B (October 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–989. doi:10.1542/peds.108.4.983. PMID 11581454. S2CID 33417584.
Hermens DF, Rowe DL, Gordon E, Williams LM (May 2006). «Integrative neuroscience approach to predict ADHD stimulant response». Expert Review of Neurotherapeutics. 6 (5): 753–763. doi:10.1586/14737175.6.5.753. PMID 16734523. S2CID 15971025.
Gilmore A, Milne R (2001). «Methylphenidate in children with hyperactivity: review and cost-utility analysis». Pharmacoepidemiology and Drug Safety. 10 (2): 85–94. doi:10.1002/pds.564. PMID 11499858. S2CID 22871134.
Mott TF, Leach L, Johnson L (August 2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–661. PMID 15298843. Արխիվացված է օրիգինալից 2011 թ․ հուլիսի 13-ին. Վերցված է 2009 թ․ ապրիլի 30-ին.
Huang YS, Tsai MH (July 2011). «Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge». CNS Drugs. 25 (7): 539–554. doi:10.2165/11589380-000000000-00000. PMID 21699268. S2CID 3449435.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, և այլք: (February 2002). «Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults». Journal of the American Academy of Child and Adolescent Psychiatry. 41 (2 Suppl): 26S–49S. doi:10.1097/00004583-200202001-00003. PMID 11833633.
Faraone SV, Wilens TE (2007). «Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion». The Journal of Clinical Psychiatry. 68 (11): 15–22. doi:10.4088/jcp.1107e28. PMID 18307377.
Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. CiteSeerX 10.1.1.507.874. doi:10.1542/peds.111.1.179. PMID 12509574. S2CID 29956425.
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, և այլք: (November 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)». The Cochrane Database of Systematic Reviews. 2016 (11): CD009885. doi:10.1002/14651858.CD009885.pub2. PMC 8763351. PMID 26599576. «the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects»
Cândido RC, Menezes de Padua CA, Golder S, Junqueira DR (January 2021). «Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults». The Cochrane Database of Systematic Reviews. Wiley. 1 (1): CD013011. doi:10.1002/14651858.cd013011.pub2. PMC 8092481. PMID 33460048.
Abelman DD (October 2017). «Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review». Harm Reduction Journal. 14 (1): 68. doi:10.1186/s12954-017-0194-6. PMC 5639593. PMID 28985738.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Fry JM (February 1998). «Treatment modalities for narcolepsy». Neurology. 50 (2 Suppl 1): S43–S48. doi:10.1212/WNL.50.2_Suppl_1.S43. PMID 9484423. S2CID 36824088.
Mitler MM (December 1994). «Evaluation of treatment with stimulants in narcolepsy». Sleep. 17 (8 Suppl): S103–S106. doi:10.1093/sleep/17.suppl_8.S103. PMID 7701190.
Dell'Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC (December 2014). «Wake-promoting pharmacotherapy for psychiatric disorders». Current Psychiatry Reports. 16 (12): 524. doi:10.1007/s11920-014-0524-2. PMID 25312027. S2CID 26314915.
Leonard BE, McCartan D, White J, King DJ (April 2004). «Methylphenidate: A review of its neuropharmacological, neuropsychological, and adverse clinical effects». Human Psychopharmacology. 19 (3): 151–180. doi:10.1002/hup.579. PMID 15079851. S2CID 21173346.
Bahji A, Mesbah-Oskui L (September 2021). «Comparative efficacy and safety of stimulant-type medications for depression: A systematic review and network meta-analysis». Journal of Affective Disorders. 292: 416–423. doi:10.1016/j.jad.2021.05.119. PMID 34144366.
Pary R, Scarff JR, Jijakli A, Tobias C, Lippmann S (April 2015). «A Review of Psychostimulants for Adults With Depression». Federal Practitioner. 32 (Suppl 3): 30S–37S. PMC 6375494. PMID 30766117.
Rozans M, Dreisbach A, Lertora JJ, Kahn MJ (January 2002). «Palliative uses of methylphenidate in patients with cancer: a review». Journal of Clinical Oncology. 20 (1): 335–339. doi:10.1200/JCO.20.1.335. PMID 11773187.
Smith KR, Kahlon CH, Brown JN, Britt RB (September 2021). «Methylphenidate use in geriatric depression: A systematic review». International Journal of Geriatric Psychiatry. 36 (9): 1304–1312. doi:10.1002/gps.5536. PMID 33829530. S2CID 233184870.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL (May 2018). «Pharmacological interventions for apathy in Alzheimer's disease». The Cochrane Database of Systematic Reviews. 5 (6): CD012197. doi:10.1002/14651858.CD012197.pub2. PMC 6494556. PMID 29727467.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 19-ին. Վերցված է 2018 թ․ նոյեմբերի 14-ին.
Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). «Psychostimulants and cognition: a continuum of behavioral and cognitive activation». Pharmacological Reviews. 66 (1): 193–221. doi:10.1124/pr.112.007054. PMC 3880463. PMID 24344115.
Agay N, Yechiam E, Carmel Z, Levkovitz Y (July 2010). «Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults». Psychopharmacology. 210 (4): 511–519. doi:10.1007/s00213-010-1853-4. PMID 20424828. S2CID 17083986.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). «Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration». Pharmacotherapy. 26 (10): 1501–1510. doi:10.1592/phco.26.10.1501. PMC 1794223. PMID 16999660.
Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). «Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing». Sports Medicine. 43 (5): 301–311. doi:10.1007/s40279-013-0030-4. PMID 23456493. S2CID 30392999.
Humphreys C, Garcia-Bournissen F, Ito S, Koren G (July 2007). «Exposure to attention deficit hyperactivity disorder medications during pregnancy». Canadian Family Physician. 53 (7): 1153–1155. PMC 1949295. PMID 17872810.
Ornoy A (February 2018). «Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation». Pharmaceutical Research. 35 (3): 46. doi:10.1007/s11095-017-2323-z. PMID 29411149. S2CID 3663423.
Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). «Development of a rational scale to assess the harm of drugs of potential misuse». Lancet. 369 (9566): 1047–1053. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (September 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». BMC Psychiatry. Springer Science and Business Media LLC. 13 (1): 237. doi:10.1186/1471-244x-13-237. PMC 3852277. PMID 24074240.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ (June 2013). «Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study». European Neuropsychopharmacology. 23 (6): 542–554. doi:10.1016/j.euroneuro.2012.06.004. PMID 22809706. S2CID 23148548.
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261 (inactive 2024 թ․ հունվարի 31). PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2024 (link)
Jaanus SD (1992). «Ocular side effects of selected systemic drugs». Optometry Clinics. 2 (4): 73–96. PMID 1363080.
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, և այլք: (March 2013). «Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents». Journal of Child Psychology and Psychiatry, and Allied Disciplines. 54 (3): 227–246. doi:10.1111/jcpp.12036. PMID 23294014.
Poulton A (August 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. doi:10.1136/adc.2004.056952. PMC 1720538. PMID 16040876.
Hinshaw SP, Arnold LE (January 2015). «ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge». Wiley Interdisciplinary Reviews. Cognitive Science. 6 (1): 39–52. doi:10.1002/wcs.1324. PMC 4280855. PMID 25558298.
Findling RL, Dinh S (March 2014). «Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)». CNS Drugs. 28 (3): 217–228. doi:10.1007/s40263-014-0141-y. PMC 3933749. PMID 24532028.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). «Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature». Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
Wingo AP, Ghaemi SN (2008). «Frequency of stimulant treatment and of stimulant-associated mania / hypomania in bipolar disorder patients». Psychopharmacology Bulletin. 41 (4): 37–47. PMID 19015628.
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261. PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
«FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 20. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, և այլք: (November 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. doi:10.1056/NEJMoa1110212. PMC 4943074. PMID 22043968.
«FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 15. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, և այլք: (December 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. doi:10.1001/jama.2011.1830. PMC 3350308. PMID 22161946.
Gordon N (1999). «Attention deficit hyperactivity disorder: Possible causes and treatment». International Journal of Clinical Practice. 53 (7): 524–528. PMID 10692738.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews. 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews (Systematic Review). 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Spiller HA, Hays HL, Aleguas A (July 2013). «Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management». CNS Drugs. 27 (7): 531–543. doi:10.1007/s40263-013-0084-8. PMID 23757186. S2CID 40931380.
Bruggisser M, Bodmer M, Liechti ME (2011). «Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets». Swiss Medical Weekly. 141: w13267. doi:10.4414/smw.2011.13267. PMID 21984207.
Nestler EJ, Barrot M, Self DW (September 2001). «DeltaFosB: A sustained molecular switch for addiction». Proceedings of the National Academy of Sciences of the United States of America. 98 (20): 11042–11046. Bibcode:2001PNAS...9811042N. doi:10.1073/pnas.191352698. PMC 58680. PMID 11572966.
Nestler EJ (December 2012). «Transcriptional mechanisms of drug addiction». Clinical Psychopharmacology and Neuroscience. 10 (3): 136–143. doi:10.9758/cpn.2012.10.3.136. PMC 3569166. PMID 23430970.
Morton WA, Stockton GG (October 2000). «Methylphenidate Abuse and Psychiatric Side Effects». Primary Care Companion to the Journal of Clinical Psychiatry. 2 (5): 159–164. doi:10.4088/PCC.v02n0502. PMC 181133. PMID 15014637.
Steiner H, van Waes V (January 2013). «Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants». Progress in Neurobiology. 100: 60–80. doi:10.1016/j.pneurobio.2012.10.001. PMC 3525776. PMID 23085425.
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (June 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. doi:10.1093/sleep/28.6.667. PMID 16477952.
Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). «Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens». Proceedings of the National Academy of Sciences of the United States of America. 106 (8): 2915–2920. Bibcode:2009PNAS..106.2915K. doi:10.1073/pnas.0813179106. PMC 2650365. PMID 19202072.
Nestler EJ (December 2013). «Cellular basis of memory for addiction». Dialogues in Clinical Neuroscience. 15 (4): 431–443. doi:10.31887/DCNS.2013.15.4/enestler. PMC 3898681. PMID 24459410.
Ruffle JK (November 2014). «Molecular neurobiology of addiction: what's all the (Δ)FosB about?». The American Journal of Drug and Alcohol Abuse. 40 (6): 428–437. doi:10.3109/00952990.2014.933840. PMID 25083822. S2CID 19157711.
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (April 2008). «Serotonin syndrome induced by augmentation of SSRI with methylphenidate». Psychiatry and Clinical Neurosciences. 62 (2): 246. doi:10.1111/j.1440-1819.2008.01767.x. PMID 18412855. S2CID 5659107.
Türkoğlu S (2015). «Serotonin syndrome with sertraline and methylphenidate in an adolescent». Clinical Neuropharmacology. 38 (2): 65–66. doi:10.1097/WNF.0000000000000075. PMID 25768857. S2CID 38523209.
Park YM, Jung YK (May 2010). «Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (4): 719–720. doi:10.1016/j.pnpbp.2010.03.016. PMID 20298736. S2CID 31984813.
Patrick KS, González MA, Straughn AB, Markowitz JS (January 2005). «New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder». Expert Opinion on Drug Delivery. 2 (1): 121–143. doi:10.1517/17425247.2.1.121. PMID 16296740. S2CID 25026467.
Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS (June 2000). «Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol». Drug Metabolism and Disposition. 28 (6): 620–624. PMID 10820132.
Markowitz JS, Logan BK, Diamond F, Patrick KS (August 1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–366. doi:10.1097/00004714-199908000-00013. PMID 10440465.
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, և այլք: (March 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics». Clinical Pharmacology and Therapeutics. 81 (3): 346–353. doi:10.1038/sj.clpt.6100082. PMC 3188424. PMID 17339864.
Roberts SM, DeMott RP, James RC (1997). «Adrenergic modulation of hepatotoxicity». Drug Metabolism Reviews. 29 (1–2): 329–353. doi:10.3109/03602539709037587. PMID 9187524.
Markowitz JS, Patrick KS (June 2008). «Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter?». Journal of Clinical Psychopharmacology. 28 (3 Suppl 2): S54–S61. doi:10.1097/JCP.0b013e3181733560. PMID 18480678.
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (February 2007). «Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity». Behavioural Pharmacology. 18 (1): 39–51. doi:10.1097/fbp.0b013e3280143226. PMID 17218796. S2CID 20232871.
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (December 2006). «A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study». Journal of Child and Adolescent Psychopharmacology. 16 (6): 687–698. doi:10.1089/cap.2006.16.687. PMID 17201613. S2CID 22895177.
Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE (2006). «A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder». The Canadian Journal of Clinical Pharmacology. 13 (1): e50–e62. PMID 16456216. Արխիվացված է օրիգինալից (PDF) 2011 թ․ դեկտեմբերի 15-ին.
Heal DJ, Pierce DM (2006). «Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system». CNS Drugs. 20 (9): 713–738. doi:10.2165/00023210-200620090-00002. PMID 16953648. S2CID 39535277.
Iversen L (January 2006). «Neurotransmitter transporters and their impact on the development of psychopharmacology». British Journal of Pharmacology. 147 (Suppl 1): S82–S88. doi:10.1038/sj.bjp.0706428. PMC 1760736. PMID 16402124.
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002 թ․ հունվարի 1). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. doi:10.1177/070674370200601s05. PMID 12685517. S2CID 9132302.
Hodgkins P, Shaw M, Coghill D, Hechtman L (September 2012). «Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options». European Child & Adolescent Psychiatry. 21 (9): 477–492. doi:10.1007/s00787-012-0286-5. PMC 3432777. PMID 22763750.
Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, և այլք: (September 2013). «Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies». The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Frodl T, Skokauskas N (February 2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J (September 1996). «Relationship between psychostimulant-induced "high" and dopamine transporter occupancy». Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10388–10392. Bibcode:1996PNAS...9310388V. doi:10.1073/pnas.93.19.10388. PMC 38394. PMID 8816810.
Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, և այլք: (August 2008). «Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence». Drug and Alcohol Dependence. 96 (3): 222–232. doi:10.1016/j.drugalcdep.2008.03.010. PMC 3652530. PMID 18468815.
Heal DJ, Gosden J, Smith SL (December 2014). «Dopamine reuptake transporter (DAT) "inverse agonism" – a novel hypothesis to explain the enigmatic pharmacology of cocaine». Neuropharmacology. 87: 19–40. doi:10.1016/j.neuropharm.2014.06.012. PMID 24953830. S2CID 4660652.
Viggiano D, Vallone D, Sadile A (2004). «Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling». Neural Plasticity. 11 (1–2): 97–114. doi:10.1155/NP.2004.97. PMC 2565441. PMID 15303308.
Miller GM (January 2011). «The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity». Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
Eiden LE, Weihe E (January 2011). «VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse». Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.
Sulzer D, Cragg SJ, Rice ME (August 2016). «Striatal dopamine neurotransmission: regulation of release and uptake». Basal Ganglia. 6 (3): 123–148. doi:10.1016/j.baga.2016.02.001. PMC 4850498. PMID 27141430.
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ (February 2009). «The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor». Die Pharmazie. 64 (2): 123–125. PMID 19322953.
Volz TJ (December 2008). «Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate». Current Neuropharmacology. 6 (4): 379–385. doi:10.2174/157015908787386041. PMC 2701286. PMID 19587858.

ncbi.nlm.nih.gov

Robison LS, Ananth M, Hadjiargyrou M, Komatsu DE, Thanos PK (May 2017). «Chronic oral methylphenidate treatment reversibly increases striatal dopamine transporter and dopamine type 1 receptor binding in rats». Journal of Neural Transmission. 124 (5): 655–667. doi:10.1007/s00702-017-1680-4. PMC 5400672. PMID 28116523.
Spencer RC, Devilbiss DM, Berridge CW (June 2015). «The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex». Biological Psychiatry. 77 (11): 940–950. doi:10.1016/j.biopsych.2014.09.013. PMC 4377121. PMID 25499957.
Busardò FP, Kyriakou C, Cipolloni L, Zaami S, Frati P (2016). «From Clinical Application to Cognitive Enhancement: The Example of Methylphenidate». Current Neuropharmacology. 14 (1): 17–27. doi:10.2174/1570159x13666150407225902. PMC 4787280. PMID 26813119.
Repantis D, Bovy L, Ohla K, Kühn S, Dresler M (February 2021). «Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine». Psychopharmacology. 238 (2): 441–451. doi:10.1007/s00213-020-05691-w. PMC 7826302. PMID 33201262.
Montgomery KA (June 2008). «Sexual desire disorders». Psychiatry. 5 (6): 50–55. PMC 2695750. PMID 19727285.
Bagot KS, Kaminer Y (April 2014). «Efficacy of stimulants for cognitive enhancement in non-attention deficit hyperactivity disorder youth: A systematic review». Addiction. 109 (4): 547–557. doi:10.1111/add.12460. PMC 4471173. PMID 24749160.
Lange KW, Reichl S, Lange KM, Tucha L, Tucha O (December 2010). «The history of attention deficit hyperactivity disorder». Attention Deficit and Hyperactivity Disorders. 2 (4): 241–255. doi:10.1007/s12402-010-0045-8. PMC 3000907. PMID 21258430.
Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V (2021 թ․ հունիսի 2). «Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity». Neuropsychiatric Disease and Treatment. 13: 1741–1751. doi:10.2147/NDT.S130444. PMC 5505611. PMID 28740389.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, և այլք: (November 2011). «ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit / hyperactivity disorder in children and adolescents». Pediatrics. 128 (5): 1007–1022. doi:10.1542/peds.2011-2654. PMC 4500647. PMID 22003063.
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, և այլք: (November 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)». The Cochrane Database of Systematic Reviews. 2016 (11): CD009885. doi:10.1002/14651858.CD009885.pub2. PMC 8763351. PMID 26599576. «the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects»
Cândido RC, Menezes de Padua CA, Golder S, Junqueira DR (January 2021). «Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults». The Cochrane Database of Systematic Reviews. Wiley. 1 (1): CD013011. doi:10.1002/14651858.cd013011.pub2. PMC 8092481. PMID 33460048.
Abelman DD (October 2017). «Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review». Harm Reduction Journal. 14 (1): 68. doi:10.1186/s12954-017-0194-6. PMC 5639593. PMID 28985738.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Pary R, Scarff JR, Jijakli A, Tobias C, Lippmann S (April 2015). «A Review of Psychostimulants for Adults With Depression». Federal Practitioner. 32 (Suppl 3): 30S–37S. PMC 6375494. PMID 30766117.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL (May 2018). «Pharmacological interventions for apathy in Alzheimer's disease». The Cochrane Database of Systematic Reviews. 5 (6): CD012197. doi:10.1002/14651858.CD012197.pub2. PMC 6494556. PMID 29727467.
Wood S, Sage JR, Shuman T, Anagnostaras SG (January 2014). «Psychostimulants and cognition: a continuum of behavioral and cognitive activation». Pharmacological Reviews. 66 (1): 193–221. doi:10.1124/pr.112.007054. PMC 3880463. PMID 24344115.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ (October 2006). «Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration». Pharmacotherapy. 26 (10): 1501–1510. doi:10.1592/phco.26.10.1501. PMC 1794223. PMID 16999660.
Humphreys C, Garcia-Bournissen F, Ito S, Koren G (July 2007). «Exposure to attention deficit hyperactivity disorder medications during pregnancy». Canadian Family Physician. 53 (7): 1153–1155. PMC 1949295. PMID 17872810.
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (September 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». BMC Psychiatry. Springer Science and Business Media LLC. 13 (1): 237. doi:10.1186/1471-244x-13-237. PMC 3852277. PMID 24074240.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261 (inactive 2024 թ․ հունվարի 31). PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2024 (link)
Poulton A (August 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. doi:10.1136/adc.2004.056952. PMC 1720538. PMID 16040876.
Hinshaw SP, Arnold LE (January 2015). «ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge». Wiley Interdisciplinary Reviews. Cognitive Science. 6 (1): 39–52. doi:10.1002/wcs.1324. PMC 4280855. PMID 25558298.
Findling RL, Dinh S (March 2014). «Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)». CNS Drugs. 28 (3): 217–228. doi:10.1007/s40263-014-0141-y. PMC 3933749. PMID 24532028.
de Sousa A, Kalra G (January 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. doi:10.4103/0973-1229.87261. PMC 3353606. PMID 22654382.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
«FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 20. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, և այլք: (November 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. doi:10.1056/NEJMoa1110212. PMC 4943074. PMID 22043968.
«FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 15. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, և այլք: (December 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. doi:10.1001/jama.2011.1830. PMC 3350308. PMID 22161946.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews. 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, և այլք: (May 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews (Systematic Review). 5 (5): CD012069. doi:10.1002/14651858.CD012069.pub2. PMC 6494554. PMID 29744873.
Nestler EJ, Barrot M, Self DW (September 2001). «DeltaFosB: A sustained molecular switch for addiction». Proceedings of the National Academy of Sciences of the United States of America. 98 (20): 11042–11046. Bibcode:2001PNAS...9811042N. doi:10.1073/pnas.191352698. PMC 58680. PMID 11572966.
Nestler EJ (December 2012). «Transcriptional mechanisms of drug addiction». Clinical Psychopharmacology and Neuroscience. 10 (3): 136–143. doi:10.9758/cpn.2012.10.3.136. PMC 3569166. PMID 23430970.
Morton WA, Stockton GG (October 2000). «Methylphenidate Abuse and Psychiatric Side Effects». Primary Care Companion to the Journal of Clinical Psychiatry. 2 (5): 159–164. doi:10.4088/PCC.v02n0502. PMC 181133. PMID 15014637.
Steiner H, van Waes V (January 2013). «Addiction-related gene regulation: risks of exposure to cognitive enhancers vs. other psychostimulants». Progress in Neurobiology. 100: 60–80. doi:10.1016/j.pneurobio.2012.10.001. PMC 3525776. PMID 23085425.
Kim Y, Teylan MA, Baron M, Sands A, Nairn AC, Greengard P (February 2009). «Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens». Proceedings of the National Academy of Sciences of the United States of America. 106 (8): 2915–2920. Bibcode:2009PNAS..106.2915K. doi:10.1073/pnas.0813179106. PMC 2650365. PMID 19202072.
Nestler EJ (December 2013). «Cellular basis of memory for addiction». Dialogues in Clinical Neuroscience. 15 (4): 431–443. doi:10.31887/DCNS.2013.15.4/enestler. PMC 3898681. PMID 24459410.
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, և այլք: (March 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics». Clinical Pharmacology and Therapeutics. 81 (3): 346–353. doi:10.1038/sj.clpt.6100082. PMC 3188424. PMID 17339864.
Iversen L (January 2006). «Neurotransmitter transporters and their impact on the development of psychopharmacology». British Journal of Pharmacology. 147 (Suppl 1): S82–S88. doi:10.1038/sj.bjp.0706428. PMC 1760736. PMID 16402124.
Hodgkins P, Shaw M, Coghill D, Hechtman L (September 2012). «Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options». European Child & Adolescent Psychiatry. 21 (9): 477–492. doi:10.1007/s00787-012-0286-5. PMC 3432777. PMID 22763750.
Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, և այլք: (September 2013). «Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies». The Journal of Clinical Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, Lieberman J (September 1996). «Relationship between psychostimulant-induced "high" and dopamine transporter occupancy». Proceedings of the National Academy of Sciences of the United States of America. 93 (19): 10388–10392. Bibcode:1996PNAS...9310388V. doi:10.1073/pnas.93.19.10388. PMC 38394. PMID 8816810.
Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, և այլք: (August 2008). «Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence». Drug and Alcohol Dependence. 96 (3): 222–232. doi:10.1016/j.drugalcdep.2008.03.010. PMC 3652530. PMID 18468815.
Viggiano D, Vallone D, Sadile A (2004). «Dysfunctions in dopamine systems and ADHD: evidence from animals and modeling». Neural Plasticity. 11 (1–2): 97–114. doi:10.1155/NP.2004.97. PMC 2565441. PMID 15303308.
Miller GM (January 2011). «The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity». Journal of Neurochemistry. 116 (2): 164–176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.
Eiden LE, Weihe E (January 2011). «VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse». Annals of the New York Academy of Sciences. 1216 (1): 86–98. Bibcode:2011NYASA1216...86E. doi:10.1111/j.1749-6632.2010.05906.x. PMC 4183197. PMID 21272013.
Sulzer D, Cragg SJ, Rice ME (August 2016). «Striatal dopamine neurotransmission: regulation of release and uptake». Basal Ganglia. 6 (3): 123–148. doi:10.1016/j.baga.2016.02.001. PMC 4850498. PMID 27141430.
Volz TJ (December 2008). «Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate». Current Neuropharmacology. 6 (4): 379–385. doi:10.2174/157015908787386041. PMC 2701286. PMID 19587858.

dailymed.nlm.nih.gov

«Ritalin- methylphenidate hydrochloride tablet». DailyMed. 2021 թ․ հունիսի 26. Արխիվացված օրիգինալից 2017 թ․ մարտի 20-ին. Վերցված է 2022 թ․ մարտի 26-ին.
«Daytrana- methylphenidate patch». DailyMed. 2021 թ․ հունիսի 15. Արխիվացված օրիգինալից 2022 թ․ մարտի 19-ին. Վերցված է 2022 թ․ մարտի 26-ին.
«Concerta- methylphenidate hydrochloride tablet, extended release». DailyMed. 2021 թ․ հուլիսի 1. Արխիվացված օրիգինալից 2017 թ․ մարտի 26-ին. Վերցված է 2022 թ․ մարտի 26-ին.

novartis.com

pharma.us.novartis.com

«Ritalin LA (methylphenidate hydrochloride) extended-release capsules» (PDF). Novartis. Արխիվացված է օրիգինալից (PDF) 2011 թ․ հուլիսի 20-ին.

pharmaceutical-journal.com

«Narcotics monitoring board reports 66% increase in global consumption of methylphenidate». The Pharmaceutical Journal. Royal Pharmaceutical Society. 294 (7853). 2015 թ․ մարտի 4. doi:10.1211/PJ.2015.20068042. Արխիվացված օրիգինալից 2018 թ․ դեկտեմբերի 19-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.

psu.edu

citeseerx.ist.psu.edu

Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. CiteSeerX 10.1.1.507.874. doi:10.1542/peds.111.1.179. PMID 12509574. S2CID 29956425.

rxlist.com

«Focalin XR». RxList. Արխիվացված օրիգինալից 2020 թ․ օգոստոսի 6-ին. Վերցված է 2020 թ․ փետրվարի 5-ին.

semanticscholar.org

api.semanticscholar.org

Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2022 թ․ մայիսի 26-ին. Վերցված է 2022 թ․ հունիսի 12-ին.
Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP (January 2019). «Use of cognitive enhancers: methylphenidate and analogs». European Review for Medical and Pharmacological Sciences. 23 (1): 3–15. doi:10.26355/eurrev_201901_16741. PMID 30657540. S2CID 58643522.
Arnsten AF, Li BM (June 2005). «Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions». Biological Psychiatry. 57 (11): 1377–1384. doi:10.1016/j.biopsych.2004.08.019. PMID 15950011. S2CID 22992765.
Capp PK, Pearl PL, Conlon C (May 2005). «Methylphenidate HCl: therapy for attention deficit hyperactivity disorder». Expert Review of Neurotherapeutics. 5 (3): 325–331. doi:10.1586/14737175.5.3.325. PMID 15938665. S2CID 43406596.
Greenfield B, Hechman L (January 2005). «Treatment of attention deficit hyperactivity disorder in adults». Expert Review of Neurotherapeutics. 5 (1): 107–121. doi:10.1586/14737175.5.1.107. PMID 15853481. S2CID 38706248.
Vitiello B (October 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–989. doi:10.1542/peds.108.4.983. PMID 11581454. S2CID 33417584.
Hermens DF, Rowe DL, Gordon E, Williams LM (May 2006). «Integrative neuroscience approach to predict ADHD stimulant response». Expert Review of Neurotherapeutics. 6 (5): 753–763. doi:10.1586/14737175.6.5.753. PMID 16734523. S2CID 15971025.
Gilmore A, Milne R (2001). «Methylphenidate in children with hyperactivity: review and cost-utility analysis». Pharmacoepidemiology and Drug Safety. 10 (2): 85–94. doi:10.1002/pds.564. PMID 11499858. S2CID 22871134.
Huang YS, Tsai MH (July 2011). «Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge». CNS Drugs. 25 (7): 539–554. doi:10.2165/11589380-000000000-00000. PMID 21699268. S2CID 3449435.
Wilens TE, Faraone SV, Biederman J, Gunawardene S (January 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. CiteSeerX 10.1.1.507.874. doi:10.1542/peds.111.1.179. PMID 12509574. S2CID 29956425.
Fry JM (February 1998). «Treatment modalities for narcolepsy». Neurology. 50 (2 Suppl 1): S43–S48. doi:10.1212/WNL.50.2_Suppl_1.S43. PMID 9484423. S2CID 36824088.
Dell'Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC (December 2014). «Wake-promoting pharmacotherapy for psychiatric disorders». Current Psychiatry Reports. 16 (12): 524. doi:10.1007/s11920-014-0524-2. PMID 25312027. S2CID 26314915.
Leonard BE, McCartan D, White J, King DJ (April 2004). «Methylphenidate: A review of its neuropharmacological, neuropsychological, and adverse clinical effects». Human Psychopharmacology. 19 (3): 151–180. doi:10.1002/hup.579. PMID 15079851. S2CID 21173346.
Smith KR, Kahlon CH, Brown JN, Britt RB (September 2021). «Methylphenidate use in geriatric depression: A systematic review». International Journal of Geriatric Psychiatry. 36 (9): 1304–1312. doi:10.1002/gps.5536. PMID 33829530. S2CID 233184870.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 19-ին. Վերցված է 2018 թ․ նոյեմբերի 14-ին.
Agay N, Yechiam E, Carmel Z, Levkovitz Y (July 2010). «Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults». Psychopharmacology. 210 (4): 511–519. doi:10.1007/s00213-010-1853-4. PMID 20424828. S2CID 17083986.
Roelands B, de Koning J, Foster C, Hettinga F, Meeusen R (May 2013). «Neurophysiological determinants of theoretical concepts and mechanisms involved in pacing». Sports Medicine. 43 (5): 301–311. doi:10.1007/s40279-013-0030-4. PMID 23456493. S2CID 30392999.
Ornoy A (February 2018). «Pharmacological Treatment of Attention Deficit Hyperactivity Disorder During Pregnancy and Lactation». Pharmaceutical Research. 35 (3): 46. doi:10.1007/s11095-017-2323-z. PMID 29411149. S2CID 3663423.
Nutt D, King LA, Saulsbury W, Blakemore C (March 2007). «Development of a rational scale to assess the harm of drugs of potential misuse». Lancet. 369 (9566): 1047–1053. doi:10.1016/S0140-6736(07)60464-4. PMID 17382831. S2CID 5903121.
Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ (June 2013). «Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study». European Neuropsychopharmacology. 23 (6): 542–554. doi:10.1016/j.euroneuro.2012.06.004. PMID 22809706. S2CID 23148548.
Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). «Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature». Clinical Neuropharmacology. 33 (4): 204–206. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
Spiller HA, Hays HL, Aleguas A (July 2013). «Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management». CNS Drugs. 27 (7): 531–543. doi:10.1007/s40263-013-0084-8. PMID 23757186. S2CID 40931380.
Ruffle JK (November 2014). «Molecular neurobiology of addiction: what's all the (Δ)FosB about?». The American Journal of Drug and Alcohol Abuse. 40 (6): 428–437. doi:10.3109/00952990.2014.933840. PMID 25083822. S2CID 19157711.
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (April 2008). «Serotonin syndrome induced by augmentation of SSRI with methylphenidate». Psychiatry and Clinical Neurosciences. 62 (2): 246. doi:10.1111/j.1440-1819.2008.01767.x. PMID 18412855. S2CID 5659107.
Türkoğlu S (2015). «Serotonin syndrome with sertraline and methylphenidate in an adolescent». Clinical Neuropharmacology. 38 (2): 65–66. doi:10.1097/WNF.0000000000000075. PMID 25768857. S2CID 38523209.
Park YM, Jung YK (May 2010). «Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (4): 719–720. doi:10.1016/j.pnpbp.2010.03.016. PMID 20298736. S2CID 31984813.
Patrick KS, González MA, Straughn AB, Markowitz JS (January 2005). «New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder». Expert Opinion on Drug Delivery. 2 (1): 121–143. doi:10.1517/17425247.2.1.121. PMID 16296740. S2CID 25026467.
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (February 2007). «Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity». Behavioural Pharmacology. 18 (1): 39–51. doi:10.1097/fbp.0b013e3280143226. PMID 17218796. S2CID 20232871.
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (December 2006). «A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study». Journal of Child and Adolescent Psychopharmacology. 16 (6): 687–698. doi:10.1089/cap.2006.16.687. PMID 17201613. S2CID 22895177.
Heal DJ, Pierce DM (2006). «Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system». CNS Drugs. 20 (9): 713–738. doi:10.2165/00023210-200620090-00002. PMID 16953648. S2CID 39535277.
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002 թ․ հունվարի 1). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. doi:10.1177/070674370200601s05. PMID 12685517. S2CID 9132302.
Frodl T, Skokauskas N (February 2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331.
Heal DJ, Gosden J, Smith SL (December 2014). «Dopamine reuptake transporter (DAT) "inverse agonism" – a novel hypothesis to explain the enigmatic pharmacology of cocaine». Neuropharmacology. 87: 19–40. doi:10.1016/j.neuropharm.2014.06.012. PMID 24953830. S2CID 4660652.

upenn.edu

repository.upenn.edu

Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2022 թ․ մայիսի 26-ին. Վերցված է 2022 թ․ հունիսի 12-ին.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 19-ին. Վերցված է 2018 թ․ նոյեմբերի 14-ին.

web.archive.org

«Methylphenidate Hydrochloride Monograph for Professionals». Drugs.com. AHFS. Արխիվացված օրիգինալից 2018 թ․ դեկտեմբերի 19-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2022 թ․ մայիսի 26-ին. Վերցված է 2022 թ․ հունիսի 12-ին.
«Ritalin- methylphenidate hydrochloride tablet». DailyMed. 2021 թ․ հունիսի 26. Արխիվացված օրիգինալից 2017 թ․ մարտի 20-ին. Վերցված է 2022 թ․ մարտի 26-ին.
Preedy VR (2016). Neuropathology of Drug Addictions and Substance Misuse. Vol. 3: General processes and mechanisms, prescription medications, caffeine and areca, polydrug misuse, emerging addictions, and non-drug addictions. Academic Press. էջ 651. ISBN 9780128006771. Արխիվացված օրիգինալից 2021 թ․ օգոստոսի 29-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.
«Narcotics monitoring board reports 66% increase in global consumption of methylphenidate». The Pharmaceutical Journal. Royal Pharmaceutical Society. 294 (7853). 2015 թ․ մարտի 4. doi:10.1211/PJ.2015.20068042. Արխիվացված օրիգինալից 2018 թ․ դեկտեմբերի 19-ին. Վերցված է 2018 թ․ դեկտեմբերի 19-ին.
«Methylphenidate». DrugBank. Արխիվացված է օրիգինալից 2019 թ․ հունվարի 31-ին. Վերցված է 2019 թ․ հունվարի 30-ին.
Mott TF, Leach L, Johnson L (August 2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–661. PMID 15298843. Արխիվացված է օրիգինալից 2011 թ․ հուլիսի 13-ին. Վերցված է 2009 թ․ ապրիլի 30-ին.
«eEML - Electronic Essential Medicines List». list.essentialmeds.org. Արխիվացված օրիգինալից 2020 թ․ մարտի 26-ին. Վերցված է 2020 թ․ մարտի 26-ին.
Ilieva IP, Hook CJ, Farah MJ (June 2015). «Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis». Journal of Cognitive Neuroscience. 27 (6): 1069–1089. doi:10.1162/jocn_a_00776. PMID 25591060. S2CID 15788121. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 19-ին. Վերցված է 2018 թ․ նոյեմբերի 14-ին.
Twohey M (2006 թ․ մարտի 26). «Pills become an addictive study aid». JS Online. Արխիվացված է օրիգինալից 2007 թ․ օգոստոսի 15-ին. Վերցված է 2007 թ․ դեկտեմբերի 2-ին.
«Daytrana- methylphenidate patch». DailyMed. 2021 թ․ հունիսի 15. Արխիվացված օրիգինալից 2022 թ․ մարտի 19-ին. Վերցված է 2022 թ․ մարտի 26-ին.
«Methylphenidate: Use During Pregnancy and Breastfeeding». Drugs.com. Արխիվացված է օրիգինալից 2018 թ․ հունվարի 2-ին.
Rissardo JP, Caprara AL (2020). «Oromandibular dystonia secondary to methylphenidate: A case report and literature review». Int Arch Health Sci. 7: 108–111. doi:10.4103/iahs.iahs_71_19 (inactive 2022 թ․ դեկտեմբերի 31). Արխիվացված օրիգինալից 2021 թ․ նոյեմբերի 15-ին. Վերցված է 2021 թ․ նոյեմբերի 15-ին – via Gale Academic OneFile.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2022 (link) CS1 սպաս․ չպիտակված ազատ DOI (link)
«Ritalin LA (methylphenidate hydrochloride) extended-release capsules» (PDF). Novartis. Արխիվացված է օրիգինալից (PDF) 2011 թ․ հուլիսի 20-ին.
«Methylphenidate ADHD medications: Drug safety communication – risk of long-lasting erections». U.S. Food and Drug Administration (FDA). 2013 թ․ դեկտեմբերի 17. Արխիվացված է օրիգինալից 2013 թ․ դեկտեմբերի 17-ին. Վերցված է 2013 թ․ դեկտեմբերի 17-ին.
«FDA drug safety communication: Safety review update of medications used to treat attention-ceficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 20. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, և այլք: (November 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. doi:10.1056/NEJMoa1110212. PMC 4943074. PMID 22043968.
«FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 2011 թ․ դեկտեմբերի 15. Արխիվացված օրիգինալից 2013 թ․ հոկտեմբերի 30-ին. Վերցված է 2013 թ․ նոյեմբերի 4-ին.
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, և այլք: (December 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. doi:10.1001/jama.2011.1830. PMC 3350308. PMID 22161946.
Heedes G, Ailakis J. «Methylphenidate hydrochloride (PIM 344)». INCHEM. International Programme on Chemical Safety. Արխիվացված օրիգինալից 2015 թ․ հունիսի 23-ին. Վերցված է 2015 թ․ հունիսի 23-ին.
«Concerta- methylphenidate hydrochloride tablet, extended release». DailyMed. 2021 թ․ հուլիսի 1. Արխիվացված օրիգինալից 2017 թ․ մարտի 26-ին. Վերցված է 2022 թ․ մարտի 26-ին.
«Focalin XR». RxList. Արխիվացված օրիգինալից 2020 թ․ օգոստոսի 6-ին. Վերցված է 2020 թ․ փետրվարի 5-ին.
«Concerta XL 18 mg – 54 mg prolonged release tablets». eMC. Արխիվացված է օրիգինալից 2017 թ․ հոկտեմբերի 17-ին.
«Concerta». Drugs.com. 2018 թ․ հոկտեմբերի 1. Արխիվացված օրիգինալից 2018 թ․ սեպտեմբերի 29-ին. Վերցված է 2019 թ․ մարտի 11-ին.

worldcat.org

Neinstein L (2009). Handbook of Adolescent Health Care. Philadelphia, PA: Wolters Kluwer Health / Lippincott Williams & Wilkins. ISBN 978-0-7817-9020-8. OCLC 226304727.^:722